InSightec Launches ExAblate(R) One and ExAblate(R) OR Systems at CIRSE 2010

New & Advanced ExAblate Systems Offer Superior Treatment for a Multitude of Commercial and Research Indications in Women's Health and Oncology

TIRAT CARMEL, Israel, September 29, 2010 - InSightec Ltd., the global leader in MR guided Focused Ultrasound
technology (MRgFUS) announced today that it will be launching ExAblate(R) One
for the treatment of uterine fibroids, adenomyosis and research options in
women's health and the ExAblate(R) OR system as the Operating Room of the
future at the upcoming Cardiovascular and Interventional Radiological Society
of Europe (CIRSE) 2010 meeting.

(Logo: www.newscom.com/cgi-bin/prnh/20100929/410802-a )

(Logo: www.newscom.com/cgi-bin/prnh/20100929/410802-b )

The ExAblate(R) family of systems employs Focused Ultrasound to
non-invasively heat and destroy targeted tissue under MR guidance. The MRI
system, the most advanced imaging modality available today, identifies and
targets tumors, while providing real time temperature monitoring of the
treated tissue.

With experience in treating over 6000 patients at more than 80 centers
around the world, the ExAblate family of systems offers a proven and mature
platform for commercially approved treatments as well as research options for
a wide range of clinical indications.

Innovative ExAblate(R) One expands treatment choices for women suffering
from uterine fibroids and adenomyosis. Recent advances in ExAblate(R)
technology now enable the treatment of large and vascular fibroids as well as
adenomyosis, broadening the patient base. The ability to treat greater
fibroid volumes is expected to result in greater clinical efficacy.
ExAblate(R) significantly improves adenomyosis symptoms, and in many cases
can improve a patient's chances of overcoming infertility caused by the
condition.

Patients treated for uterine fibroids or adenomyosis typically return to
their normal routine within twenty four hours of the procedure, a major
improvement over most fibroid treatment techniques. A growing number of women
have become pregnant following the ExAblate treatment. Studies have shown
that MRgFUS may even improve fertility in women suffering from infertility
caused by uterine fibroids.(1)

Experience at sites around the world has shown that ExAblate
significantly increases patient interest in MRgFUS treatment and facility
traffic. A leading site in Tokyo, Japan reported that the number of patients
treated for uterine fibroids increased by 550% in one year.(2)

The ExAblate treatment has also been proven as a cost-effective
alternative to current treatments, meeting acceptable criteria for optimal
cost-effectiveness in fibroid treatment.(3)

"MR guided Focused Ultrasound (MRgFUS) use in the treatment of uterine
fibroids has been an accepted and viable option for increasing numbers of
women for several years now. However, with the enhancements offered by
ExAblate(R) One we are able to offer even more women the option of treatment
with an effective, dedicated women's health platform with predictable
results." Said Professor Wladyslaw M Gedroyc, MD, Head of Radiology, St.
Mary's Hospital, London, UK. "In addition to the benefits to patients, such
as preservation of the uterus and improved chances of fertility, we have also
seen a significant reduction in treatment time."

The ExAblate(R) OR platform is a Non-invasive Image Guided and Controlled
Acoustic Operating Room. The system incorporates interchangeable cradles for
each application that are interfaced with a single common table. ExAblate(R)
OR offers both commercially approved and research treatment options for a
multitude of clinical indications such as: uterine fibroids and adenomyosis,
breast cancer, prostate cancer, pain palliation of bone metastases and
various other indications.

ExAblate(R) One and ExAblate(R) OR are compatible with both GE
Healthcare's Signa and Discovery MRI product lines and have a newly designed
patient bed with ergonomic advantage for patients, streamlined user interface
and improved usability for physicians.

"Our vision has been to provide a dedicated ExAblate system which truly
offers expanded non-invasive treatment choice and has a proven safety
profile. Since the market introduction of the ExAblate(R) 2000 in 2004,
clinicians and researchers have continued to strive to further improve and
enhance the system based on innovation and accumulating clinical data and
knowledge, "said Dr. Kobi Vortman, President and CEO of InSightec. "We are
the only MR guided Focused Ultrasound technology provider to offer such a
proven and mature image guided and controlled acoustic surgery platform".

The new ExAblate(R) One and ExAblate(R) OR patient bed will be featured
at the InSightec booth # 44 at CIRSE (2-6, October 2010, Valencia, Spain).
InSightec will also be hosting a satellite symposium at CIRSE, on October 3rd
at which leading researchers will discuss their work in various fields using
the ExAblate system. To learn more about InSightec's planned activities at
CIRSE please visit: www.insightec.com

1 Rabinovici J, David M, Fukunishi H, Morita Y, Gostout BS, Stewart EA,
for the MRgFUS Study Group. Pregnancy Outcome After Magnetic Resonance-guided
Focused Ultrasound Surgery (MRgFUS) for Conservative Treatment of Uterine
Fibroids, Fertility & Sterility, 2008.

2 Yutaka Morita, Tetsuya Nakamura Introduction of ExAblate(R) 2000
Dramatically Increases Revenues of OB/GYN Department in One Year InSightec
Clinical Report Vol. 2, No. 1

3 O'Sullivan AK, Thompson D, Chu P, Lee DW, Stewart EA, Weinstein MC.
Cost-Effectiveness of Magnetic Resonance guided Focused Ultrasound for the
Treatment of Uterine Fibroids, Int. J of Technology Assessment in Health
Care, 2009, 25(1): 14-25

About ExAblate(R)

The ExAblate(R)One and OR systems are built on enhancements made through
dedication to research and development and InSightec's unparalleled
experience and innovation in partnering with physicians around the world on
clinical research.

The ExAblate(R) 2000 received CE mark in 2002 and the Food and Drug
administration (FDA) approval in 2004 for the treatment of uterine fibroids.
The system received the European CE mark for pain palliation of bone
metastases in June 2007 and for adenomyosis in June 2010. ExAblate 2000 has
won numerous innovation awards and has been used to treat thousands of
patients around the world.

About InSightec

InSightec Ltd. is a privately-held company owned by Elbit Imaging,
General Electric, MediTech Advisors, LLC and employees. It was founded in
1999 to develop the breakthrough MR guided Focused Ultrasound technology and
transform it into the next generation operating room. Headquartered near
Haifa, Israel, the company has over 160 employees and has invested more than
$130 million in research, development, and clinical investigations. Its U.S.
headquarters are located in Dallas, Texas. For more information, please go
to: www.insightec.com/

Note to editors:

ExAblate(R) One received a CE mark for adenomyosis treatment in June
2010. It is not approved by the FDA.

    Media Contact:

    For further information please contact:

    Dr. Jane Brearley
    Waggener Edstrom Worldwide
    Tower House
    10 Southampton Street
    Covent Garden
    London
    WC2E 7HA

    Email: jbrearley@waggeneredstrom.com
    Phone: +44(0)20-7632-3800

For further information please contact: Dr. Jane Brearley, Waggener Edstrom Worldwide, Tower House, 10 Southampton Street, Covent Garden, London, WC2E 7HA, Email: jbrearley at waggeneredstrom.com, Phone: +44(0)20-7632-3800